Pre-earnings options volume in Crispr Therapeutics is normal with puts leading calls 9:8. Implied volatility suggests the market is anticipating a move near 7.2%, or $5.65, after results are released. Median move over the past eight quarters is 7.6%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
- Crispr Therapeutics initiated with a Peer Perform at Wolfe Research
- Cathie Wood’s ARK Investment bought 280K shares of Crispr Therapeutics today
- Crispr Therapeutics Secures Funding Through Share Issuance
- Crispr Therapeutics announces $280M registered diect offering